Form 4: Enzo Biochem Director Sells All Shares in Merger

Enzo Biochem Director Jonathan Couchman disposed of all his direct and indirect holdings in the company, totaling 605,134 shares and RSUs, following the completion of the merger with Bethpage Parent, Inc. at $0.70 per share.

Summary

• Jonathan Couchman, a Director of Enzo Biochem Inc. (ENZB), disposed of all his beneficial ownership in the company on August 20, 2025.
• The disposition was a result of the merger between Enzo Biochem and Bethpage Parent, Inc., where Enzo Biochem became a wholly-owned subsidiary of Bethpage Parent, Inc.
• Each share of Enzo Biochem common stock was converted into the right to receive $0.70 in cash.
• Restricted Stock Units (RSUs) held by the director were also converted into cash based on the $0.70 per share merger consideration.
• The total number of shares and RSUs disposed of was 605,134, comprising 142,897 directly held RSUs and 462,237 indirectly held common shares.
• Indirect holdings included shares held by Xstelos Holdings, Inc. (130,000 shares), Myrexis, Inc. (40,000 shares), Couchman Family Fund (15,000 shares), and various retirement accounts (277,237 shares).
• Following these transactions, Jonathan Couchman's beneficial ownership in Enzo Biochem is zero.

Sentiment

Score: 7

Explanation: The filing reports the expected completion of a merger, resulting in the disposition of all shares held by a director at a pre-determined cash price. This indicates a successful conclusion to a strategic transaction, providing liquidity to shareholders.

Positives

• Shareholders, including the reporting person, received a cash consideration of $0.70 per share for their common stock and RSUs, providing liquidity and a defined return.
• The completion of the merger indicates a successful strategic transaction for the company.

Negatives

• The reporting person, a director, no longer holds any beneficial ownership in Enzo Biochem, indicating a complete exit from the company's equity.

Future Outlook

The filing does not provide forward-looking statements or guidance, as it reports a completed transaction.

Industry Context

This filing reflects the finalization of an acquisition in the biotechnology or life sciences sector, where Enzo Biochem, a company involved in healthcare and diagnostics, was acquired by Bethpage Parent, Inc. Such mergers are common in industries undergoing consolidation or strategic realignment.

Stakeholder Impact

• Shareholders: Received $0.70 per share in cash, providing a definitive return and liquidity.

Key Dates

Keywords

Enzo Biochem, ENZB, Merger, Acquisition, SEC Form 4, Insider Trading, Beneficial Ownership, Jonathan Couchman, Bethpage Parent Inc., Cash Consideration, Restricted Stock Units, Corporate Governance